



US008008449B2

(12) **United States Patent**
Korman et al.

(10) **Patent No.:** **US 8,008,449 B2**
(45) **Date of Patent:** **Aug. 30, 2011**

(54) **HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS**

7,329,639 B2	2/2008	Hardy et al.
7,332,582 B2	2/2008	Hardy et al.
7,488,802 B2	2/2009	Collins et al.
2003/0232323 A1	12/2003	Freeman et al.
2004/0073957 A1	4/2004	Tomizuka et al.
2007/0065427 A1	3/2007	Freeman et al.
2007/0202100 A1	8/2007	Wood et al.
2008/0025979 A1	1/2008	Honjo et al.

(75) Inventors: **Alan J. Korman**, Piedmont, CA (US);
Mohan Srinivasan, San Jose, CA (US);
Changyu Wang, Fremont, CA (US);
Mark J. Selby, San Francisco, CA (US);
Bingliana Chen, Alameda, CA (US);
Josephine M. Cardarelli, San Carlos, CA (US)

FOREIGN PATENT DOCUMENTS

EP	0742795	9/1998
EP	1537878	6/2005
JP	07291996 A	11/1998
WO	WO/97/07671	3/1997
WO	WO 01/14557	3/2001
WO	WO 02/079499	10/2002
WO	WO 2003/006636	1/2003
WO	WO 03/033644	4/2003
WO	WO 03/042402	5/2003
WO	WO 2004/056875	7/2004
WO	WO 2004/072286	8/2004
WO	WO 2006/021955	3/2006

(73) Assignees: **Medarex, Inc.**, Princeton, NJ (US); **Ono Pharmaceutical Co., Ltd.**, Osaka (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 413 days.

(21) Appl. No.: **11/913,217**

(22) PCT Filed: **May 2, 2006**

(86) PCT No.: **PCT/JP2006/309606**

§ 371 (c)(1),
(2), (4) Date: **Jan. 29, 2009**

(87) PCT Pub. No.: **WO2006/121168**

PCT Pub. Date: **Nov. 16, 2006**

(65) **Prior Publication Data**

US 2009/0217401 A1 Aug. 27, 2009

Related U.S. Application Data

(60) Provisional application No. 60/679,466, filed on May 9, 2005, provisional application No. 60/738,434, filed on Nov. 21, 2005, provisional application No. 60/748,919, filed on Dec. 8, 2005.

(51) **Int. Cl.**
C07K 16/28 (2006.01)

(52) **U.S. Cl.** **530/388.15**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,629,204 A	5/1997	Honjo et al.
5,698,520 A	12/1997	Honjo et al.
5,897,862 A	4/1999	Hardy et al.
6,632,927 B2 *	10/2003	Adair et al. 530/387.3
6,632,976 B1	10/2003	Tomizuka et al.
6,803,192 B1	10/2004	Chen
6,808,710 B1	10/2004	Wood et al.
6,936,704 B1	8/2005	Freeman et al.
7,029,674 B2	4/2006	Carreno et al.
7,041,474 B2	5/2006	Kingsbury
7,101,550 B2	9/2006	Wood et al.
7,105,328 B2	9/2006	Wood et al.
7,122,372 B2	10/2006	Hardy et al.

OTHER PUBLICATIONS

Rudikoff et al. 1982, Proc. Natl. Acad. Sci. USA, , 79: 1979-1983.*
Panka et al., 1988, Proc. Natl. Acad. Sci. USA, 85: 3080-3084.*
Wong RM et al., "Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs," *Int Immunol.* (2007), 19(10):1223-34.
Berger et al., "Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies," *Clin Cancer Res.* (2008); 14(10):3044-51.
Blank et al., "PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8⁺T Cells"; *Cancer Research*; (2004); 64:1140-1145.
Cox et al., "A directory of human germ-line V_κ segments reveals a strong bias in their Usage"; *Eur. J. Immunol.*; (1994); 24:827-836.
Koga et al., "Blockade of the Interaction between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts"; *Arterioscler. Thromb. Vasc. Biol.*; (2004); 24(11):2057-2062.

(Continued)

Primary Examiner — Ilia Ouspenski

(74) *Attorney, Agent, or Firm* — Baker Botts L.L.P.

(57) **ABSTRACT**

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

23 Claims, 58 Drawing Sheets